A phase II study of prostatic acid phosphatase-pulsed dendritic cells (Provenge) [sipuleucel T] in combination with bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2013
At a glance
- Drugs Sipuleucel-T (Primary) ; Bevacizumab
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Aug 2007 Status changed from in progress to completed.
- 30 Sep 2005 New trial record.